Drug Profile
Research programme: rheumatoid arthritis therapy - Entelos/Organon
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Entelos; Organon
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in USA
- 20 Oct 2009 Preclinical development is ongoing in USA
- 07 Dec 2007 Preclinical development is ongoing